Background and objectives
• In today's economically constrained environment, payers have responded to the potentially high cost of new oncology medicines by conducting value-for-money assessments through national or regional pricing and reimbursement (P&R) and health technology assessment (HTA) agencies.
• Assessments may introduce the potential for discrepancies between the clinically eligible population (under the license) and the population that is eligible for treatment through public reimbursement.
• This study analyzed whether gross domestic product (GDP) per capita (GDPPC) and health expenditure as a proportion of GDP are associated with the national access restrictions imposed in various markets.
Methods
• Six common cancers were identified (breast, kidney, lung, melanoma, multiple myeloma, and prostate). New oncology therapies • Analyses are based on publicly available national HTA/P&R documents. Where no relevant documents were identified, other publicly available information and communication with country-level experts were used to ratify the reimbursement status. Where no conclusions could be drawn, the outcome of the assessment was considered to result in no restriction.
• Using the estimated median OS gain with the new treatment (from the EMA regulatory documents), potential years of life lost (YLL) as a result of any restrictions were estimated. • For each reimbursement outcome, the impact of the decision was established in terms of the number of patients without access and YLL (assuming each assessment to be independent). • The relationship between restrictions (nature and impact on patients) and two financial metrics for each country were explored (Table 1) 
Results

Reimbursement decisions
• Of the 892 possible reimbursement decisions (Figure 2 ), 316 (35%) resulted in a complete or partial restriction (Table 2 ). Assumptions: 100% market uptake for every drug/indication; each reimbursement assessment is independent; assessments can be added together to estimate impact; impact in Germany is assumed to be zero, as all approvals are in line with the license; 
Relationship between reimbursement restrictions and financial metrics
• As shown in Figure 3A , Poland and Portugal, with lower GDPPC, applied complete restrictions in 94% and 60% of assessments, respectively. However, Spain, with a somewhat higher but still relatively low GDPPC, applied a lower rate of complete restrictions (2%) at the national level; however, regional restrictions were not taken into account.
• Rates of complete restrictions varied among countries with similar GDPPC, such as Australia, Belgium, Canada, and Germany (0-31% of assessments).
• Analyses based on health care expenditure ( Figure 3B) showed: • Germany, France, and the Netherlands, with ≥10% health expenditure as a % of GDP, imposed restrictions in 0-17% of indications.
• Countries with <9% health expenditure as a % of GDP (e.g., Poland, Australia, Italy, and the UK) restricted access to a varying degree (37-98% of indications). 
Discussion and conclusions
• Access to cancer therapies via public reimbursement varies between countries, and the nature of the restrictions and their impact on patients is heterogeneous.
• Patterns of restrictions do not correlate with GDP; however, healthcare expenditure as a proportion of GDP was moderately predictive of the extent of restriction.
• Analysis of reimbursement outcomes (i.e., patients affected and YLL) with GDPPC and health expenditure as a proportion of GDP indicated that these correlated in terms of ranking, but the relationship could not easily be explained using linear regression models. The findings suggest that, in the countries included in this study, inequitable access to cancer treatments resulting from discrepancies between the licensed and reimbursed populations cannot be explained by GDPPC.
• Although the rank correlation between the proportion of assessments with restrictions in each country and GDPPC was −0.71, the relationship was not linear (R 2 = 0.51, Table 3 ); however, there was a stronger linear relationship between health expenditure as a proportion of GDP and the proportion of reimbursement restrictions in each country (R 2 = 0.70, Table 3 ). Relationship between impact of reimbursement outcomes and country financial metrics • There were no clear patterns of association between GDPPC and the total number of patients affected or YLL ( Figure 4A and Table 3 ).
• Analyses suggest that the number of patients without access increases with health expenditure but the relationship is not linear ( Figure 4B and Table 3 ). 
